Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

PREPARE: Patient Centered Perioperative Experience

Not Applicable

Active, not recruiting

Conditions: Minimally Invasive Surgery (MIS) Hysterectomy

Interventions: Other: usual care
Other: Educational video

First Posted Date: 2020-07-15

Last Posted Date: 2025-06-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 275

Registration Number: NCT04472117

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack (All Protocol Activities), Commack, New York, United States

and more 4 locations

Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields

Phase 2

Recruiting

Conditions: Skin Toxicity
Glioblastoma
Recurrent Glioblastoma

Interventions: Drug: Clindamycin Phosphate
Drug: Triamcinolone Acetonide

First Posted Date: 2020-07-13

Last Posted Date: 2024-11-08

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 58

Registration Number: NCT04469075

Locations: 🇺🇸
Northwestern University, Evanston, Illinois, United States
🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 5 locations

A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma

Phase 2

Withdrawn

Conditions: Multiple Myeloma

Interventions: Drug: 89Zr-DFO-daratumumab
Diagnostic Test: PET/CT

First Posted Date: 2020-07-13

Last Posted Date: 2022-07-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT04467281

Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma

Phase 1

Recruiting

Conditions: Follicular Lymphoma

Interventions: Diagnostic Test: cfDNA testing
Other: sample of saliva or fingernail clipping
Diagnostic Test: pre-treatment test specimen
Diagnostic Test: PET/CT, CT, or MRI testing

First Posted Date: 2020-07-13

Last Posted Date: 2024-08-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 100

Registration Number: NCT04468841

Locations: 🇺🇸
Memorial Sloan Kettering Commack (All Protocol Activities), Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States

and more 4 locations

19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

Phase 1

Active, not recruiting

Conditions: Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma
Indolent Non-Hodgkin Lymphoma
Marginal Zone Lymphoma
Primary CNS Lymphoma
Diffuse Large B Cell Lymphoma
Primary Mediastinal Large B Cell Lymphoma
Chronic Lymphocytic Leukemia
Waldenstrom Macroglobulinemia
Burkitt's Lymphoma

Interventions: Drug: 19(T2)28z1xx CAR T cells

First Posted Date: 2020-07-09

Last Posted Date: 2024-08-23

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT04464200

Locations: 🇺🇸
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States

and more 4 locations

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

Phase 1

Completed

Conditions: Thyroid Carcinoma
Thyroid Cancer
Thyroid Cancer, Follicular
Thyroid Cancer (Follicular Cell)
Thyroid Cancer, Papillary
BRAF V600E Mutation Positive

Interventions: Diagnostic Test: I-124 PET/CT lesion dosimetry
Drug: Vemurafenib
Drug: Copanlisib

First Posted Date: 2020-07-08

Last Posted Date: 2025-05-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 8

Registration Number: NCT04462471

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center (All protocol activities), New York, New York, United States
🇺🇸
Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre, New York, United States

and more 4 locations

Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer

Phase 2

Active, not recruiting

Conditions: Colorectal Adenocarcinoma

Interventions: Drug: Temozolomide (TMZ)
Drug: Cisplatin
Drug: Nivolumab

First Posted Date: 2020-07-07

Last Posted Date: 2025-03-11

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 18

Registration Number: NCT04457284

Locations: 🇺🇸
Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States

and more 4 locations

Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer

Not Applicable

Recruiting

Conditions: Early Stage Breast Cancer

Interventions: Other: Aerobic Training

First Posted Date: 2020-07-07

Last Posted Date: 2025-04-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 152

Registration Number: NCT04458532

Locations: 🇺🇸
Hartford Healthcare Cancer Institute @ Hartford Hospital (Data Collection Only), Hartford, Connecticut, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Study of PRP Treatment for Hair Loss After Cancer Therapy in Women With Breast Cancer

Early Phase 1

Active, not recruiting

Conditions: Alopecia

Interventions: Procedure: Platelet Rich Plasma system

First Posted Date: 2020-07-07

Last Posted Date: 2025-05-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT04459650

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States

Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma

Phase 3

Active, not recruiting

Conditions: Multiple Myeloma
Non-Hodgkin Lymphoma
Hodgkin Disease

Interventions: Other: Acupuncture
Drug: opioid
Other: Assessments

First Posted Date: 2020-07-07

Last Posted Date: 2024-12-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 299

Registration Number: NCT04459416

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸
Seattle Cancel Care Alliance (Data Collection Only), Seattle, Washington, United States

Home Terms & Conditions Privacy Policy